The public view is the crawlable proof. The same sourced dataset is available through REST and MCP for agents, research scripts, and back-office tools.
| Date | Insider | Role | Action | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | George Jeffrey P. | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | Drapkin Kimberlee C | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | McCollum James W | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | Thunen Shelley B | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | Guerard Frederic | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | Scheiner Zachary | Director | Grant(A) | 22K | — | $0 |
| Jun 15, 2026 | Ra Capital Management, L.P. | Director, 10% Owner | Grant(A) | 22K | — | $0 |
| Mar 27, 2026 | Chevallard Daniel R. | Chief Financial Officer | Buy(P) | 8K | $8.57 | $64K |
| Mar 27, 2026 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Buy(P) | 28K | $8.95 | $251K |
| Mar 27, 2026 | George Jeffrey P. | Director | Buy(P) | 6K | $8.92 | $50K |
| Jan 2, 2026 | Chevallard Daniel R. | Chief Financial Officer | Grant(A) | 14K | — | $0 |
| Jan 2, 2026 | Chevallard Daniel R. | Chief Financial Officer | Grant(A) | 84K | — | $0 |
| Jan 2, 2026 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 358K | — | $0 |
| Jan 2, 2026 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 84K | — | $0 |
| Jan 2, 2026 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 14K | — | $0 |
| Jan 2, 2026 | Odrich Marc | Chief Medical Officer | Grant(A) | 14K | — | $0 |
| Jan 2, 2026 | Odrich Marc | Chief Medical Officer | Grant(A) | 84K | — | $0 |
| Nov 17, 2025 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 10K | $2.08 | $21K |
| Nov 17, 2025 | Olsson Shawn | Chief Commercial Officer | Sell(S) | 4K | $25.74 | $108K |
| Nov 17, 2025 | Olsson Shawn | Chief Commercial Officer | Sell(S) | 6K | $26.37 | $153K |
| Nov 17, 2025 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 10K | — | $0 |
| Nov 7, 2025 | Chevallard Daniel R. | Chief Financial Officer | Buy(P) | 2K | $22.76 | $50K |
| Nov 7, 2025 | Chevallard Daniel R. | Chief Financial Officer | Buy(P) | 20 | $22.71 | $454 |
| Nov 7, 2025 | McCollum James W | Director | Buy(P) | 11K | $22.79 | $239K |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 34K | $45.35 | $1.6M |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 50K | $45.35 | $2.3M |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 83K | $46.41 | $3.9M |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 58K | $46.41 | $2.7M |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 177 | $47.01 | $8K |
| Sep 30, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 123 | $47.01 | $6K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 49K | $41.59 | $2.1M |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 24K | $41.59 | $1.0M |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 132 | $43.30 | $6K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 20K | $43.00 | $866K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 268 | $43.30 | $12K |
| Sep 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 41K | $43.00 | $1.8M |
| Aug 26, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 44K | $38.97 | $1.7M |
| Aug 26, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 2K | $39.50 | $67K |
| Aug 26, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 3K | $39.50 | $137K |
| Aug 26, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 22K | $38.97 | $844K |
| Aug 25, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 1K | $39.92 | $42K |
| Aug 25, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 50K | $39.53 | $2.0M |
| Aug 25, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 25K | $39.53 | $979K |
| Aug 25, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 2K | $39.92 | $86K |
| Aug 22, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 20K | $40.03 | $820K |
| Aug 22, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 6K | $40.59 | $230K |
| Aug 22, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 3K | $40.59 | $114K |
| Aug 22, 2025 | Versant Ventures VII GP, L.P. | 10% Owner | Sell(S) | 10K | $40.03 | $403K |
| Aug 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 15K | $38.56 | $582K |
| Aug 18, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 31K | $38.56 | $1.2M |
| Aug 15, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 70K | $39.50 | $2.8M |
| Aug 15, 2025 | Versant Venture Capital VI, L.P. | 10% Owner | Sell(S) | 145K | $39.50 | $5.7M |
| Jul 10, 2025 | Versant Ventures VII GP-GP, LLC | 10% Owner | Sell(S) | 191K | $34.00 | $6.5M |
| Jun 27, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 200K | $30.47 | $6.1M |
| Jun 20, 2025 | Versant Ventures VI GP, L.P. | 10% Owner | Sell(S) | 101K | $30.35 | $3.1M |
| Jun 20, 2025 | Versant Ventures VI GP, L.P. | 10% Owner | Sell(S) | 134K | $30.25 | $4.1M |
| Jun 18, 2025 | Versant Ventures VI GP, L.P. | 10% Owner | Sell(S) | 100K | $29.95 | $3.0M |
| Jun 11, 2025 | RA Capital Healthcare Fund LP | Director, 10% Owner | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | Scheiner Zachary | Director | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | McCollum James W | Director | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | Thunen Shelley B | Director | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | Guerard Frederic | Director | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | Drapkin Kimberlee C | Director | Grant(A) | 14K | — | $0 |
| Jun 11, 2025 | George Jeffrey P. | Director | Grant(A) | 14K | — | $0 |
| Jun 10, 2025 | Versant Vantage II GP-GP, LLC | 10% Owner | Sell(S) | 350K | $29.00 | $10.2M |
| Apr 9, 2025 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 1K | $2.08 | $3K |
| Apr 9, 2025 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 1K | — | $0 |
| Mar 7, 2025 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Option exercise(M) | 4K | $1.04 | $4K |
| Mar 7, 2025 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Option exercise(M) | 4K | — | $0 |
| Jan 9, 2025 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 279K | — | $0 |
| Jan 9, 2025 | Chevallard Daniel R. | Chief Financial Officer | Grant(A) | 70K | — | $0 |
| Jan 9, 2025 | Odrich Marc | Chief Medical Officer | Grant(A) | 80K | — | $0 |
| Jan 9, 2025 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 80K | — | $0 |
| Dec 16, 2024 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 3K | $2.08 | $7K |
| Dec 16, 2024 | Olsson Shawn | Chief Commercial Officer | Option exercise(M) | 3K | — | $0 |
| Jul 22, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Option exercise(M) | 45K | $1.04 | $47K |
| Jul 22, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Option exercise(M) | 45K | — | $0 |
| May 14, 2024 | Chevallard Daniel R. | Chief Financial Officer | Buy(P) | 3K | $15.68 | $50K |
| May 13, 2024 | McCollum James W | Director | Buy(P) | 31K | $15.99 | $501K |
| Mar 21, 2024 | Versant Vantage II GP, L.P. | 10% Owner | Other(J) | 598K | — | — |
| Mar 21, 2024 | Scheiner Zachary | Director | Grant(A) | 27K | — | $0 |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Buy(P) | 65K | $15.03 | $977K |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Buy(P) | 933K | $15.03 | $14.0M |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 2.4M | — | — |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 695K | — | — |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 165K | — | — |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 55K | — | — |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 27K | — | $0 |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 5K | — | — |
| Mar 21, 2024 | RA Capital Nexus Fund II, L.P. | Director, 10% Owner | Grant(A) | 11K | — | — |
| Mar 21, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 316K | — | $0 |
| Mar 21, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 83K | — | $0 |
| Mar 21, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 387K | — | $0 |
| Mar 21, 2024 | Schimmelpennink Evert B. | President, CEO and Secretary, Director | Grant(A) | 475K | — | $0 |
| Mar 21, 2024 | Odrich Marc | Chief Medical Officer | Grant(A) | 100K | — | $0 |
| Mar 21, 2024 | Odrich Marc | Chief Medical Officer | Grant(A) | 66K | — | $0 |
| Mar 21, 2024 | Odrich Marc | Chief Medical Officer | Grant(A) | 105K | — | $0 |
| Mar 21, 2024 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 68K | — | $0 |
| Mar 21, 2024 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 30K | — | $0 |
| Mar 21, 2024 | Olsson Shawn | Chief Commercial Officer | Grant(A) | 51K | — | $0 |
Insider transactions sourced from SEC EDGAR Form 4 filings, normalized within minutes of acceptance. "Buy"/"Sell" mark open-market transactions (codes P/S), the tradeable signal. Awards, option exercises and tax-withholding are shown with their raw code. All data is public domain.
Coverage: Form 4 filings indexed 2021-03-29 → 2026-07-14. Earlier history is backfilling; this window widens as it deepens.
Programmatic access via the Arkolith API & MCP server (insider.transactions, insider.company).